This specification provides an anti-EpoR peptide. The present invention provides a peptide having the structure of the following formula (I): X 1 -SCH(A 1 )(A 2 )(A 3 )(A 4 )(A 5 )(A 6 )V(A 7 )( A 8 )-X 2 [In the formula, X 1 is the amino terminal side of the peptide, X 2 is the carboxy terminal side of the peptide, A 1 is M, or F, substituted or unsubstituted by halogen atoms or hydroxyl groups, Phenylglycine or phenethylglycine, A 2 is A, d-alanine or G, A 3 is P, homoproline or A, A 4 is M, L, A or I, A 5 Is T or A, A 6 is M, or W, F, Y, β-pertryptophan, α-naphthylalanine, β-naphthylalanine, or substituted or unsubstituted by methyl or halogen atoms Quinolinylalanine, A 7 is C, homocysteine or penicillamine, A 8 is K, R, or not present].本說明書提供一種抗EpoR胜肽。本發明提供一種具有如下式(I)之結構之胜肽：X1-SCH(A1)(A2)(A3)(A4)(A5)(A6)V(A7)(A8)-X2[式中，X1為胜肽之胺基末端側，X2為胜肽之羧基末端側，A1為M、或經鹵素原子或者羥基取代或未經取代之F、苯基甘胺酸或苯乙基甘胺酸，A2為A、d-丙胺酸或G，A3為P、高脯胺酸或A，A4為M、L、A或I，A5為T或A，A6為M、或經甲基或者鹵素原子取代或未經取代之W、F、Y、β-高色胺酸、α-萘基丙胺酸、β-萘基丙胺酸或喹啉基丙胺酸，A7為C、高半胱胺酸或青黴胺，A8為K、R、或未存在]。
